Laparoscopic resection of locally advanced gastrointestinal stromal tumour (GIST) of the stomach following neoadjuvant imatinib chemoreduction

Christophe R. Berney*

Department of Surgery, Bankstown-Lidcombe Hospital, University of New South Wales, 68 Eldridge Road, Bankstown, NSW 2200, Australia

**Article info**

Article history:
Received 13 October 2014
Received in revised form 27 January 2015
Accepted 27 January 2015
Available online 29 January 2015

Keywords:
Laparoscopic
Stomach
Gastrointestinal stromal tumour
Neoadjuvant treatment
Imatinib
Downstaging

**Abstract**

**INTRODUCTION:** Laparoscopic resection of locally advanced gastrointestinal stromal tumours (GISTs) is rarely offered to patients as a first line of treatment.

**PRESENTATION OF CASES:** We present two cases of locally advanced gastric GISTs successfully treated with neoadjuvant imatinib and followed up by complete laparoscopic excision of the residual tumour mass. There was no evidence of local recurrence or distant metastases after a mean follow up of more than 40 months.

**DISCUSSION:** Over the last decade, the development of imatinib has totally revolutionized management of metastatic GISTs and it is now possible to achieve primary tumour downstaging of more than 80%. Unfortunately, current literature on laparoscopic excision of locally advanced gastric GISTs following neoadjuvant treatment of imatinib remains scarce. The present cases strongly suggest that this new therapeutic approach might become the preferred medical option in such clinical situation.

**CONCLUSION:** Patients with locally advanced non-metastatic gastric GISTs should be offered first-line imatinib-based cytoreductive chemotherapy as an alternative to radical debulking surgery, as a substantial proportion of them will experience significant tumour shrinkage and therefore benefit from a much less invasive laparoscopic approach.

© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Gastrointestinal stromal tumours (GISTs) arise from the interstitial cells of Cajal, specialized cells of the autonomic nervous system located within the wall of the gastrointestinal tract and responsible for paced contractions of the intestinal musculature ‘pacemakers’ as well as modulation of enteric neurotransmission [1]. The most common location of GISTs is in the stomach and accounts for around two-thirds of them, followed up by the small intestine, colon and rectum, and rarely oesophageal or appendix [2]. Diagnosis is histological and characterized by a high expression of a c-KIT proto-oncogene (CD117, tyrosine kinase receptor), and CD34 on immunohistochemistry. The prediction of malignancy remains difficult and relies on a combination of several criteria that include mitotic activity count, tumour size, presence of necrosis and invasive growth [3].

Surgery is the treatment of choice of non-metastatic GISTs when a complete R0 resection (clear margins) can be achieved with low morbidity, and routine lymphadenectomy is not required as those lesions rarely metastasize to the nearby lymph nodes [4]. With the development of stapling devices, laparoscopic wedge resection of small gastric lesions has become the preferred surgical technique as it significantly reduces post-operative pain and morbidity, shortens hospital length of stay, while maintaining adequate overall long-term clinical outcome [5].

Recently published series have demonstrated similar results with gastric GISTs larger than 5 cm in diameter, when performed by experienced surgeons [6–8]. Having said that, caution should be taken when considering laparoscopic excision of locally advanced lesions, where the need for major gastrectomy with or without ‘en bloc’ resection of neighbouring organ might be necessary. In those circumstances it would be more reasonable to favour a conventional open approach that could increase the probability of complete R0 resection.

2. Cases presentation

We present the two cases of locally advanced gastric GISTs who did benefit from a 2-stages approach and where delayed laparoscopic R0 resection could be successfully achieved, without complication. Case one, at the time an 80 years old female patient classified ASA class III with significant cardiopulmonary disease...
was investigated for anaemia. Abdominal CT-scan revealed a large heterogeneous gastric mass measuring $13 \times 13.5$ cm, arising from the greater curvature (Fig. 1) and with classical features of GIST on endoscopic ultrasound (EUS). There was no evidence of distant metastases on positron emission tomography (PET) scan and fine needle aspiration (FNA) biopsy of the lesion confirmed the diagnosis. She received neoadjuvant imatinib 400 mg per day, as a single daily dosing for a total of 6 months and a significant 70% reduction of the mass was achieved as confirmed on repeat CT-scan imaging confirmed (Fig. 2). The patient eventually underwent laparoscopic wedge excision of the gastric wall encompassing the residual GIST (Fig. 3). Although she had an uncomplicated post-operative recovery the patient was discharged home 4 weeks later as she required significant physio mobilisation before being safely discharged home. Histopathology results demonstrated an excellent response to imatinib with almost complete tumour necrosis and excision was complete (R0). Imatinib was reintroduced at one month following her surgery, but was interrupted 6 months later due to undesired side effects, mainly fluid retention, nausea and loss of appetite. She is today over 5 years post surgery with still no evidence of local recurrence or distant metastases on repeat imaging.

Case two, a 50 years old male patient when he was diagnosed with a locally advanced non-metastatic $14.5 \times 11.4$ cm gastric GIST abutting (loss of fat plane) the transverse colon. Unrelated, he also had a large cervical lump occupying most of his right thyroid lobe and corresponding to a benign follicular lesion on FNA. Other relevant problem included presence of central obesity and
a 30 pack-years smoking history. The patient received a 6-month neoadjuvant treatment of imatinib 400 mg single daily dose leading to partial tumour response (around 50%) as demonstrated on progressive CT-scan imaging, but showing clear evidence of central necrosis of the GIST. Incidentally, towards the end of his medical treatment he was found to have a left testicular mass that was replacing most of his testis on US. Tumour markers were all negative and there was no evidence of loco-regional or distant metastases on CT-scan. The patient underwent elective laparoscopic excision of the gastric GIST including partial wedge excision of the greater curvature (Fig. 4), as well as radical left orchidectomy.

‘En-bloc’ colonic resection was unnecessary as the transverse colon and its mesentery were free of tumour, with clear margins (R0) on histopathology. The testicular lesion corresponded to a 4 cm seminoma confined to the testis and the surgical margins were also free of tumour (pT1N0M0). The patient went home on the fourth post-operative day and subsequently received a single dose of adjuvant carboplatin for his seminoma. Imatinib was also recommenced following his surgery for a total of 20 months. Of interest, he underwent right thyroid lobectomy four months following his initial laparoscopic procedure and was diagnosed three months later with a metastatic seminoma, for which he received three supplementary cycles of second-line chemotherapy. The patient is currently still on complete remission from his gastric GIST and metastatic seminoma 3 1/2 years later.

**3. Discussion**

Surgery is the only potentially curative option for gastric GISTs. Unfortunately, a small proportion of them are locally advanced measuring >10 cm in size or borderline resectable at initial diagnosis, meaning that ‘en bloc’ removal of neighbouring organ might be necessary to obtain R0 tumour resection. In those situations, minimally invasive laparoscopic approach is generally unsuitable and conventional open surgery is preferred, which is unfortunate especially in high-risk patients where complication rates are expected to be higher. Those two cases are good illustrations of large gastric GISTs successfully treated laparoscopically following neoadjuvant chemotherapy, while initially unfavourable for such minimally invasive approach.

Indeed, while still controversial the currently available KIT-selective tyrosine kinase inhibitor, imatinib (Glivec, formerly known as ST1571, Novartis Pharma AG, Basel, Switzerland) may be considered as a first line of treatment in order to achieve substantial tumour chemo-reduction and improve success rate of delayed curative-intent surgery, as well as overall survival [9]. One can extrapolate that tumour down-staging of potentially excisable locally advanced GIST lesions, using neoadjuvant imatinib-based chemotherapy may ultimately allow reconsideration to a minimally invasive approach [7,10]. An appealing concept that unfortunately will necessitate a large randomized multicentre study with long-term follow up to prove its validity over conventional open surgery. In the mean time, only anecdotal observational case series may offer a partial answer.

**4. Conclusion**

In summary, patients with locally advanced non-metastatic gastric GISTs should be offered first-line neoadjuvant imatinib-based cytoreductive chemotherapy as an alternative to radical debulking surgery, as a substantial proportion of them will experience significant tumour shrinkage and therefore eventually benefit from a much less invasive laparoscopic approach.

**Conflict of interest**

None.

**Funding**

None.

**Consent**

Written informed consent was obtained from each of the two patients included in this case series for publication of this case series and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.
References

[1] L.G. Kindblom, H.E. Remotti, F. Aldenborg, J.M. Meis-Kindblom, Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal, Am. J. Pathol. 152 (1998) 1259–1269.

[2] M. Miettinen, J. Lasota, Gastrointestinal stromal tumors (GISTS): definition, occurrence, pathology, differential diagnosis and molecular genetics, Pol. J. Pathol. 54 (2003) 3–24.

[3] M. Miettinen, L.H. Sobin, J. Lasota, Gastrointestinal stromal tumors of the stomach: a clinicopathological, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up, Am. J. Surg. Pathol. 29 (2005) 52–68.

[4] M.N. Wente, M.W. Büchler, J. Weitz, Gastrointestinal stromal tumors (GIST). Surgical therapy, Chirurg 79 (2008) 638–643.

[5] J.Y. Blay, S. Bonvalot, P. Casali, H. Choi, M. Debiec-Richter, A.P. Dei Tos, J.F. Emile, A. Gronchi, P.C. Hogendoorn, H. Joensuu, A. Le Cesne, J. McClure, J. Maurel, N. Supponen, I. Ray-Coquard, P. Reichardt, R. Sciot, S. Stroobants, M. van Glabbeke, A. van Oosterom, G.D. Demetri, GIST consensus meeting panelists consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20–21 March 2004, under the auspices of ESMO, Ann. Oncol. 16 (2005) 566–5678.

[6] M. Valle, O. Federici, F. Carboni, S. Carpano, M. Benedetti, A. Garofalo, Gastrointestinal stromal tumors of the stomach: the role of laparoscopic resection. Single-centre experience of 38 cases, Surg. Endosc. 28 (2014) 1040–1047.

[7] J. Lin, C. Huang, C. Zheng, P. Li, J. Xie, J. Wang, J. Lu, Laparoscopic versus open gastric resection for larger than 5 cm primary gastric gastrointestinal stromal tumors (GIST): a size-matched comparison, Surg. Endosc. 28 (2014) 2577–2583.

[8] K.H. Kim, M.C. Kim, G.J. Jung, S.J. Kim, J.S. Jang, H.C. Kwon, Long term survival results for gastric GIST: is laparoscopic surgery for large gastric GIST feasible? World J. Surg. Oncol. 10 (2012) 230, http://dx.doi.org/10.1186/1477-7819-10-230.

[9] B.L. Eisenberg, J. Harris, C.D. Blanke, G.D. Demetri, M.C. Heinrich, J.C. Watson, J.P. Hoffman, S. Okuno, J.M. Kane, M. von Mehren, Phase II trial of neoadjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665, J. Surg. Oncol. 99 (2009) 42–47.

[10] K.K. Roggin, M.C. Posner, Modern treatment of gastrointestinal stromal tumours, World J. Gastroenterol 18 (2012) 6720–6728.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.